GLSI

MKT CAP:$395M

Greenwich Lifesciences Inc

Market Cap

$395M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$22.25+$2.78 (+14.28%)

Jun 5, 2026

52W High $33.5652W Low $7.85

Company Details

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an ...

CEO

—

IPO Date

Sep 25, 2020

Website

greenwichlifesciences.com

Key Metrics TTM

Revenue

$7.2K

+32.3% YoY

Net Income

-$16M

EPS (Diluted)

Free Cash Flow

-$9M

Revenue / Share

Gross Margin

0.0%

Operating Margin

-58223.7%

Net Margin

-217396.5%

FCF Margin

-119818.7%

P/S

55089.7x

P/E

Earnings Reports

Q1 2026

Jun 1, 2026

NEW

$3.6K-1.5%

Q3 2025

Nov 14, 2025

Q2 2025

Aug 14, 2025

Q1 2025

May 20, 2025

$3.6K-33.3%

FY 2024

Feb 26, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee